Form 4: BioMarin Director Receives Restricted Stock Units

Director Robert J. Hombach was granted 7,490 restricted stock units by BioMarin Pharmaceutical Inc. on June 2, 2026.

Summary

• Director Robert J. Hombach acquired 7,490 restricted stock units (RSUs) of BioMarin Pharmaceutical Inc. (BMRN).
• The transaction occurred on June 2, 2026.
• The acquisition of these units increased the director's total direct beneficial ownership to 49,360 shares of common stock.
• The grant was issued at no cost to the director.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation that does not signal a change in company strategy or financial health.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• None identified in this filing.

Risks

• None identified in this filing.

Future Outlook

Not applicable as this is a routine disclosure of director equity compensation.

Industry Context

StockSavvy.ai notes that routine equity grants to board members are standard corporate governance practices in the biotechnology sector, intended to incentivize long-term performance and retention of leadership.

Comparison to Industry Standards

• The grant of restricted stock units to directors is consistent with standard compensation practices for mid-to-large cap pharmaceutical companies.
• The transaction size is typical for non-executive director compensation packages.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity grant.

Next Steps

• No further actions required by the reporting person regarding this specific transaction.

Key Dates

Keywords

BioMarin Pharmaceutical, BMRN, Form 4, Insider Trading, Restricted Stock Units, Director Compensation